Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $12.50, for a total value of $25,000.00. Following the completion of the sale, the president now owns 2,924,467 shares in the company, valued at approximately $36,555,837.50. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE traded down $0.10 during midday trading on Thursday, hitting $12.00. The company’s stock had a trading volume of 115,011 shares, compared to its average volume of 75,621. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $27.10. The business’s 50 day simple moving average is $12.60 and its 200 day simple moving average is $12.67.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GYRE. Barclays PLC grew its position in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after buying an additional 43,840 shares during the last quarter. State Street Corp grew its holdings in Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares in the last quarter. FMR LLC acquired a new stake in shares of Gyre Therapeutics in the 3rd quarter worth $47,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in shares of Gyre Therapeutics during the 3rd quarter worth $334,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.